论文部分内容阅读
通过体内实验进一步证实rhPRL对机体免疫功能的调节作用,以及用于过继细胞免疫治疗的可能性。我们选用CB17 SCID纯系小鼠,腹腔注入人结肠腺癌细胞(HT29),2小时后腹腔注入尼龙毛纯化的人淋巴细胞(T/NK细胞),同时开始进行rhPRL治疗,并设HBSS对照和rhIL-2治疗对照组。结果表明,rhPRL在体内外均无直接抗癌效应,反而可促进肿瘤生长。当SCID荷瘤鼠同时移植入人的T/NK细胞时出rhPRL可明显提高T/NK细胞的抗癌效果,生存期明显延长(P<0.05)。平均生存期由70.4天延至112.1天,在对照组全部死亡时(d105),rhPRL治疗组有60％存活,且在实验终止时(>160天)仍有40％存活。分析其抗癌机理发现,rhPRL体外可直接促进人T/NK细胞增殖,其分泌上清可抑制肿瘤生长,同时发现人T/NK细胞与HT29共育4小时中rhPRL亦可直接促进杀伤活性。
The in vivo experiments further confirmed the regulation of rhPRL on immune function and the possibility of adoptive cellular immunotherapy. We used CB17 SCID pure strain mice to intraperitoneally inject human colon adenocarcinoma cells (HT29). After 2 hours, nylon wool-purified human lymphocytes (T/NK cells) were injected intraperitoneally, and rhPRL treatment was started. The HBSS control and rhIL-2 treatment control group. The results showed that rhPRL had no direct anti-cancer effect in vivo and in vitro, but could promote tumor growth instead. When SCID tumor-bearing mice were transplanted into human T/NK cells at the same time, rhPRL could significantly increase the anti-cancer effect of T/NK cells, and the survival time was significantly prolonged (P<0.05). The average survival period was extended from 70.4 days to 112.1 days. When all the control group died (d105), 60% of the patients in the rhPRL group survived, and 40% survived at the termination of the experiment (>160 days). Analysis of its anti-cancer mechanism found that rhPRL can directly promote human T / NK cell proliferation in vitro, the secretion of the supernatant can inhibit tumor growth, and found that human T / NK cells and HT29 co-bred rhPRL in 4 hours can also directly promote the killing activity.